


Spwick
486823
pt 2 of 3


Double bond geometry as shown.



RN 151539-35-4 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-(2-fluorophenyl)ethenyl]-3,7-dihydro-1,3-dipropyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 151539-37-6 CAPLUS

CN 1H-Purine-2,6-dione, 3,7-dihydro-8-[2-(4-methoxy-2,5-dimethylphenyl)ethenyl]-1,3-dipropyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 151539-41-2 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-(4-ethoxyphenyl)ethenyl]-3,7-dihydro-1,3-dipropyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 151539-43-4 CAPLUS

CN 1H-Purine-2,6-dione, 3,7-dihydro-8-[2-(4-propoxypyhenyl)ethenyl]-1,3-dipropyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 151539-48-9 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-(3-bromo-4-methoxyphenyl)ethenyl]-3,7-dihydro-1,3-dipropyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 151539-51-4 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-(2-bromo-4,5-dimethoxyphenyl)ethenyl]-3,7-dihydro-1,3-dipropyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 151539-63-8 CAPLUS

CN 1H-Purine-2,6-dione, 3,7-dihydro-8-[2-(4-methoxy-1-naphthalenyl)ethenyl]-1,3-dipropyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 151539-68-3 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-(4-butoxyphenyl)ethenyl]-3,7-dihydro-1,3-dipropyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 155271-00-4 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-(2,3-dimethoxyphenyl)ethenyl]-1,3-diethyl-3,7-

dihydro-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-08-2 CAPLUS

CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-8-[2-(4-methoxy-2,5-dimethylphenyl)ethenyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-82-2 CAPLUS


CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-8-[2-(3-nitrophenyl)ethenyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 155271-84-4 CAPLUS
CN 1H-Purine-2,6-dione,
8-[2-(3-bromophenyl)ethenyl]-1,3-diethyl-3,7-dihydro-
, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 155271-86-6 CAPLUS
CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-8-[2-[3-
(trifluoromethyl)phenyl]ethenyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 155271-88-8 CAPLUS
CN 1H-Purine-2,6-dione, 8-[2-(6-bromo-1,3-benzodioxol-5-yl)ethenyl]-1,3-
diethyl-3,7-dihydro-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 155271-90-2 CAPLUS
CN 1H-Purine-2,6-dione,
1,3-diethyl-8-[2-(2-fluorophenyl)ethenyl]-3,7-dihydro-
, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 155271-93-5 CAPLUS
CN 1H-Purine-2,6-dione, 8-(2-[1,1'-biphenyl]-4-ylethenyl)-1,3-diethyl-3,7-
dihydro-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155271-95-7 CAPLUS
CN 1H-Purine-2,6-dione, 1,3-diethyl-8-[2-(3-fluoro-4-methoxyphenyl)ethenyl]-
3,7-dihydro-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-97-9 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-(3-chloro-4-fluorophenyl)ethenyl]-1,3-diethyl-3,7-dihydro-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-99-1 CAPLUS

CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-8-[2-(7-methoxy-1,3-benzodioxol-5-yl)ethenyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155272-01-8 CAPLUS

CN 1H-Purine-2,6-dione, 1,3-diethyl-8-[2-(3-fluoro-2-methylphenyl)ethenyl]-3,7-dihydro-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155272-07-4 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-[4-(4-bromobutoxy)phenyl]ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155272-08-5 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-[4-(4-azidobutoxy)phenyl]ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155272-10-9 CAPLUS

CN Acetic acid, [4-[2-(1,3-diethyl-2,3,6,7-tetrahydro-7-methyl-2,6-dioxo-1H-purin-8-yl)ethenyl]phenoxy]-, ethyl ester, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155814-27-0 CAPLUS

CN 1H-Purine-2,6-dione,
8-[2-(3,4-dimethoxyphenyl)ethenyl]-3,7-dihydro-1,3-di-
2-propenyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155814-29-2 CAPLUS

CN 6H-Purin-6-one,
8-[2-(3,4-dimethoxyphenyl)ethenyl]-1,2,3,7-tetrahydro-1,3-
dipropyl-2-thioxo-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155814-35-0 CAPLUS

CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-8-[2-(3-
phenoxyphenyl)ethenyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 169958-97-8 CAPLUS

CN 1H-Purine-2,6-dione, 3,7-dihydro-8-[2-[3-methoxy-4-
(methoxymethoxy)phenyl]ethenyl]-1,3-dipropyl-, (E)- (9CI) (CA INDEX
NAME)

Double bond geometry as shown.



IT 147700-41-2P 147700-44-5P 147700-46-7P
151539-26-3P 151539-27-4P 151539-28-5P
151539-34-3P 151539-36-5P 151539-39-8P
151539-40-1P 151539-45-6P 151539-47-8P
151539-50-3P 151539-53-6P 151539-56-9P
151539-57-0P 151539-65-0P 155271-02-6P
155271-81-1P 155271-87-7P 155271-89-9P
155271-91-3P 155271-92-4P 155271-94-6P
155271-98-0P 155272-04-1P 155272-09-6P
155272-11-0P 155272-14-3P 155272-15-4P
155814-24-7P 155814-36-1P 169958-99-0P
175675-61-3P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological
study); PREP (Preparation); USES (Uses)


(prepn. of arylvinylxanthines as selective A2 receptor antagonists)

RN 147700-41-2 CAPLUS

CN 1H-Purine-2,6-dione,
3,7-dihydro-7-methyl-8-[2-(3-nitrophenyl)ethenyl]-1,3-

dipropyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 147700-44-5 CAPLUS

CN 1H-Purine-2,6-dione, 8-[(E)-2-(3-nitrophenyl)ethenyl]-3,7-dihydro-7-methyl-1,3-dipropyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 147700-46-7 CAPLUS

CN 1H-Purine-2,6-dione, 8-[(E)-2-(3-chlorophenyl)ethenyl]-3,7-dihydro-7-methyl-1,3-dipropyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 151539-26-3 CAPLUS

CN 1H-Purine-2,6-dione,
8-[(E)-2-(3,5-dimethoxy-4-phenylmethoxyphenyl)ethenyl]-

3,7-dihydro-7-methyl-1,3-dipropyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 151539-27-4 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-(2,3-dimethoxyphenyl)ethenyl]-3,7-dihydro-1,3-dipropyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 151539-28-5 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-(2,3-dimethoxyphenyl)ethenyl]-3,7-dihydro-7-methyl-1,3-dipropyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 151539-34-3 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-(2-chlorophenyl)ethenyl]-3,7-dihydro-7-methyl-1,3-dipropyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 151539-36-5 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-(2-fluorophenyl)ethenyl]-3,7-dihydro-7-methyl-1,3-dipropyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 151539-39-8 CAPLUS

CN 1H-Purine-2,6-dione, 3,7-dihydro-8-[2-(4-methoxy-2,5-dimethylphenyl)ethenyl]-7-methyl-1,3-dipropyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 151539-40-1 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-(3,4-dimethoxyphenyl)ethenyl]-3,7-dihydro-7-methyl-1,3-dipropyl-, (Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 151539-45-6 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-(4-butoxyphenyl)ethenyl]-3,7-dihydro-7-methyl-1,3-dipropyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 151539-47-8 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-(3,4-diethoxyphenyl)ethenyl]-3,7-dihydro-7-methyl-1,3-dipropyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 151539-50-3 CAPLUS

CN 1H-Purine-2,6-dione,
8-[2-(3-bromo-4-methoxyphenyl)ethenyl]-3,7-dihydro-7-
methyl-1,3-dipropyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 151539-53-6 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-(2-bromo-4,5-dimethoxyphenyl)ethenyl]-3,7-
dihydro-7-methyl-1,3-dipropyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 151539-56-9 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-(3-bromo-4,5-dimethoxyphenyl)ethenyl]-3,7-
dihydro-7-methyl-1,3-dipropyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 151539-57-0 CAPLUS

CN 1H-Purine-2,6-dione,
3,7-dihydro-8-[(E)-2-(3-hydroxy-4-methoxyphenyl)ethenyl]-
7-methyl-1,3-dipropyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 151539-65-0 CAPLUS

CN 1H-Purine-2,6-dione,
3,7-dihydro-8-[(E)-2-(4-methoxy-1-naphthyl)ethenyl]-7-
methyl-1,3-dipropyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-02-6 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-(2,4-dimethoxyphenyl)ethenyl]-1,3-diethyl-3,7-dihydro-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-81-1 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-(3,5-difluorophenyl)ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-87-7 CAPLUS

CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-7-methyl-8-[2-[3-(trifluoromethyl)phenyl]ethenyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-89-9 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-(6-bromo-1,3-benzodioxol-5-yl)ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-91-3 CAPLUS

CN 1H-Purine-2,6-dione, 1,3-diethyl-8-[2-(2-fluorophenyl)ethenyl]-3,7-dihydro-7-methyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-92-4 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-[4-(dimethylamino)phenyl]ethenyl]-1,3-diethyl-3,7-dihydro-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-94-6 CAPLUS

CN 1H-Purine-2,6-dione, 8-(2-[1,1'-biphenyl]-4-ylethenyl)-1,3-diethyl-3,7-dihydro-7-methyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-98-0 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-(3-chloro-4-fluorophenyl)ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155272-04-1 CAPLUS

CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-8-[2-(3-hydroxy-4-methoxyphenyl)ethenyl]-7-methyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155272-09-6 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-[(E)-3-hydroxy-4-(methoxyphenyl)but-1-enyl]ethyl]-1,3-diethyl-3,7-dihydro-7-methyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155272-11-0 CAPLUS

CN Acetic acid, [4-[2-(1,3-diethyl-2,3,6,7-tetrahydro-7-methyl-2,6-dioxo-1H-purin-8-yl)ethenyl]phenoxy]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155272-14-3 CAPLUS

CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-8-[2-(4-hydroxyphenyl)but-1-enyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155272-15-4 CAPLUS

CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-8-[2-(4-hydroxy-2,3-dimethylphenyl)ethenyl]-7-methyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155814-24-7 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-(3,4-dimethoxyphenyl)ethenyl]-7-ethyl-3,7-dihydro-1,3-dipropyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155814-36-1 CAPLUS

CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-7-methyl-8-[2-(3-phenoxyphenyl)ethenyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 169958-99-0 CAPLUS

CN 1H-Purine-2,6-dione,
3,7-dihydro-8-[(2-(4-hydroxy-3-methoxyphenyl)ethenyl)-
7-methyl-1,3-dipropyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 175675-61-3 CAPLUS

CN 1H-Purine-2,6-dione,
3,7-dihydro-8-[(2-(4-hydroxy-3-methoxyphenyl)ethenyl)-
1,3-dipropyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L22 ANSWER 39 OF 57 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.
96121270 EMBASE Document No.: 1996121270. Adenosine A(2a) receptor-mediated modulation of striatal acetylcholine release in vivo. Kurokawa M.; Koga K.; Kase H.; Nakamura J.; Kuwana Y.. Pharmaceutical Research Laboratories, Kyowa Hakko Kogyo Co., Ltd., 1188 Shimotogari, Sunto, Shizuoka 411, Japan. Journal of Neurochemistry 66/5 (1882-1888) 1996. ISSN: 0022-3042. CODEN: JONRA. Pub. Country: United States. Language: English. Summary Language: English.

AB To determine the functions of striatal adenosine A(2a) receptors in vivo, the effects of a selective agonist, 2-[4-(2-carboxyethyl)phenethylamino]-5'-N-ethyl-carboxamideadenosine hydrochloride (CGS 21680), and an antagonist, (E)-8-(3,4-dimethoxystyryl)-1,3-dipropyl-7-methylxanthine (KF17837), on acetylcholine release were investigated in the striatum of awake freely moving rats using microdialysis. Intracerebroventricular injection of CGS 21680 (10 μ g) increased acetylcholine release in striatum and KF17837 (30 mg/kg p.o.) antagonized the CGS 21680-induced acetylcholine elevation. To investigate the contribution of dopaminergic and GABAergic neurons on A(2a) receptor-mediated acetylcholine release, the effects of CGS 21680 were studied by using dopamine-depleted rats in the presence or absence of GABA antagonists. In the dopamine-depleted striatum, the intrastriatal application of CGS 21680 (0.3-30 μ M) increased extracellular acetylcholine, which was significantly greater than that in normal striatum. The CGS 21680-induced elevation of acetylcholine release was still observed in the presence of GABA antagonists bicuculline (30 μ M) and 2-hydroxysaclofen (100 μ M) and was similar in both normal and dopamine-depleted striatum. These results suggest that A(2a) agonist stimulates acetylcholine release in vivo, and this effect of A(2a) agonist is modulated by dopaminergic and GABAergic neurotransmission.

L22 ANSWER 40 OF 57 MEDLINE DUPLICATE 4
96192129 Document Number: 96192129. PubMed ID: 8627294. Adenosine A2b receptors mediate an increase in interleukin (IL)-6 mRNA and IL-6 protein synthesis in human astrogloma cells. Fiebich B L; Biber K; Gyufko K; Berger M; Bauer J; van Calker D. (Psychiatrische Klinik, Universitat Freiburg, Germany.) JOURNAL OF NEUROCHEMISTRY, (1996 Apr) 66 (4) 1426-31.
Journal code: JAV; 2985190R. ISSN: 0022-3042. Pub. country: United States.
Language: English.
AB The cytokine interleukin (IL)-6 has recently been demonstrated to play a role in the pathology of **Alzheimer's** disease (AD). The mechanisms leading to increased IL-6 levels in brains of AD patients are still unknown. Because in experimental animals ischemia increases both the levels of cytokines and the extracellular concentrations of adenosine in the brain, we hypothesized that these two phenomena may be functionally connected and that adenosine might increase IL-6 gene expression in the brain. Here we show that the mixed A1 and A2 agonist 5'-(N-ethylcarboxamido) adenosine (NECA) induces an increase in IL-6 mRNA levels and protein synthesis in the human astrocytoma cell line U373 MG. The A1-specific agonists R-phenylisopropyladenosine and cyclopentyladenosine are much less potent, and the A2a-specific agonist CGS-21860 shows only

min marginal effects. Increased levels of mRNA are already found within 30 min after NECA treatment. The A2a-selective antagonists 8-(3-chlorostyryl) caffeine and KF17837 [(E)-8-(3,4-dimethoxystyryl)-1,3-dipropyl-7-methylxanthine], which have also some antagonistic properties at A2b receptors, and the nonspecific adenosine antagonist 8-phenyltheophylline were equipotent at inhibiting the NECA-induced increase in IL-6 protein synthesis, whereas the specific A1 antagonist 8-cyclopentyl-1,3-dipropylxanthine is much less potent. The results indicate that adenosine A2b receptors participate in the regulation of the IL-6 gene in astrocytoma cells.

L22 ANSWER 41 OF 57 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.
97141557 EMBASE Document No.: 1997141557. Neuropharmacology of the adenosine A(2A) receptors. Ongini E.; Dionisotti S.; Morelli M.; Ferrere S.; Svenningsson P.; Fuxé K.; Fredholm B.B.. Dr. E. Ongini, Schering-Plough Research Institute, San Raffaele Science Park, Via Olgettina 58, I-20132 Milan, Italy. Drug Development Research 39/3-4 (450-460) 1996.

Refs: 86.

ISSN: 0272-4391. CODEN: DDREDK. Pub. Country: United States. Language: English. Summary Language: English.

AB Studies done over the last 20 years have clearly shown that the adenosine A(2A) receptors are abundant in the striatum of several animal species. A(2A) receptors have also been found in the cerebral cortex and hippocampus. The distribution of A(2A) receptors closely matches that of dopamine D2 receptors, being expressed in striatopallidal CABAergic neurons that also express enkephalin. A variety of functional and behavioural studies have shown that antagonistic interactions exist between the A(2A) and D2 receptors. Thus, blockade of A(2A) receptors mimics the action of dopamine D2 receptor agonists. More recent studies have indicated that A(2A) receptors interact more broadly with dopaminergic pathways. D1 receptors are also involved in such interactions. Altogether, a variety of data support the suggestion that A(2A) receptor antagonists have a potential for treatment of **Parkinson's** disease, whereas A(2A) receptor agonists, which inhibit motor behaviour, may possess neuroleptic properties. Great progress is being made thanks to the development of potent and selective A(2A) receptor antagonists, notably the xanthines KF 17837 and CSC, and the non-xanthine heterocycle SCH 58261. These compounds and their radiolabelled forms make it possible to elucidate the role of brain A(2A) receptors further and open the way to the development of new agents for treatment of central nervous system disorders.

L22 ANSWER 42 OF 57 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.
96076297 EMBASE Document No.: 1996076297. Clinical neurosciences and **Alzheimer's** disease. Cacabelos R.. Institute for CNS Disorders, Basic and Clin Neuroscis Res Centre, La Coruna, Spain. Clinical Science 90/3 (153-156) 1996.

ISSN: 0143-5221. CODEN: CSCIAE. Pub. Country: United Kingdom. Language: English.

L22 ANSWER 43 OF 57 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.
96039064 EMBASE Document No.: 1996039064. Selective muscarinic receptor agonists and antagonists. Eglen R.M.; Watson N.. Inst. Pharmacology and Neurobiology, Roche Biosciences, 3401, Hillview Ave, Palo Alto, CA 94304,

United States. Pharmacology and Toxicology 78/2 (59-68) 1996.
ISSN: 0901-9928. CODEN: PHTOEH. Pub. Country: Denmark. Language: English.
Summary Language: English.

AB Muscarinic receptors are composed of a family of four subtypes each of which can be distinguished pharmacologically and structurally. The physiological role of each subtype in the central and peripheral nervous systems remains to be clarified, due, in part, to a lack of agonists and antagonists with adequate subtype selectivity. Nonetheless, several agonists with functional selectivity for M1 receptors are now in advanced clinical evaluation for **Alzheimer's** disease, while selective M1/M3 antagonists may prove useful in the treatment of disorders of smooth muscle function. These novel compounds thus provide an advance over earlier therapeutics with which the clinical efficacy was compromised by the side effect profile. This review attempts to assess novel, selective agonists and antagonists, both in terms of their use in defining muscarinic receptor subtypes and their potential clinical utility.


L22 ANSWER 44 OF 57 CAPLUS COPYRIGHT 2001 ACS
1995:902791 Document No. 123:313638 Preparation of xanthine derivatives as adenosine A2 receptor inhibitors. Suzuki, Fumio; Koike, Nobuaki; Shimada, Junichi; Nakamura, Joji; Shiozaki, Shizuo; Kitamura, Shigeto; Ichikawa, Shunji; Kase, Hiroshi; Nonaka, Hiromi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. WO 9523148 A1 19950831, 48 pp. DESIGNATED

STATES:

W: AU, CA, CN, FI, HU, JP, KR, NO, NZ, US; RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE. (Japanese). CODEN: PIXXD2.

APPLICATION: WO 1995-JP267 19950223. PRIORITY: JP 1994-25736 19940223.

GI



AB Xanthine derivs. [I; R = [O(CH₂)_n-CO-R₄]_m; R₁, R₂ and R₃ are the same or different from one another and each represents hydrogen, lower alkyl, lower alkenyl or lower alkynyl; R₄ represents lower alkyl or (un)substituted aryl; R₅ and R₆ are the same or different from each other and each represents hydrogen, lower alkyl or lower alkoxy, or R₅ and R₆ are combined together to represent -O-(CH₂)_p-O- wherein p represents an integer of 1 to 3; n represents 0, 1 or 2; and m represents 1 or 2] and their pharmaceutically acceptable salts are prepd. These compds. are adenosine A₂ receptor antagonists and are useful for treating or preventing various diseases caused by hyperfunctioning of adenosine A₂ receptors, such as **Parkinson's** disease, senile dementia, depression, asthma or osteoporosis. Thus, (E)-8-(3,4-dihydroxystyryl)-7-

methyl-1,3-dipropylxanthine (prepn. given) in pyridine was treated with Ac₂O at room temp. for 5 h to give 69% (E)-8-(3,4-diacetoxystyryl)-7-methyl-1,3-dipropylxanthine. In an in vitro study using rat tissue, this at 10⁻⁷ M showed 89% inhibition of adenosine A₂ receptors.

Pharmaceutical

compns. contg. I are described.

IT 169958-70-7P 169958-71-8P 169958-72-9P
169958-73-0P 169958-74-1P 169958-75-2P
169958-76-3P 169958-77-4P 169958-78-5P
169958-79-6P 169958-80-9P 169958-81-0P
169958-82-1P 169958-83-2P 169958-84-3P
169958-85-4P 169958-86-5P 169958-87-6P
169958-88-7P 169958-89-8P 169958-90-1P
169958-91-2P 169958-92-3P 169958-93-4P
169958-94-5P 169958-95-6P 169958-96-7P

RL: BAC (Biological activity or effector, except adverse); RCT
(Reactant);


SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of xanthine derivs. as adenosine A₂ receptor inhibitors)

RN 169958-70-7 CAPPLUS

CN 1H-Purine-2,6-dione,

8-[2-[3,4-bis(acetoxy)phenyl]ethenyl]-3,7-dihydro-7-methyl-1,3-dipropyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 169958-71-8 CAPPLUS

CN 1H-Purine-2,6-dione,

8-[2-[3,4-bis(benzoyloxy)phenyl]ethenyl]-3,7-dihydro-7-methyl-1,3-dipropyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 169958-72-9 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-[3-(acetyloxy)-4-methoxyphenyl]ethenyl]-3,7-dihydro-7-methyl-1,3-dipropyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 169958-73-0 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-[4-(acetyloxy)-3-methoxyphenyl]ethenyl]-3,7-dihydro-7-methyl-1,3-dipropyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 169958-74-1 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-[4-(acetyloxy)-3-methoxyphenyl]ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 169958-75-2 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-[4-(benzoyloxy)-3-methoxyphenyl]ethenyl]-3,7-dihydro-7-methyl-1,3-dipropyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 169958-76-3 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-[4-(benzoyloxy)-3-methoxyphenyl]ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 169958-77-4 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-[4-(benzoyloxy)phenyl]ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 169958-78-5 CAPLUS

CN 1H-Purine-2,6-dione,
8-[2-[3,5-bis(acetoxy)phenyl]ethenyl]-3,7-dihydro-7-methyl-1,3-dipropyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 169958-79-6 CAPLUS

CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-8-[2-[3-methoxy-4-(2-oxopropoxy)phenyl]ethenyl]-7-methyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 169958-80-9 CAPLUS

CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-8-[2-[3-methoxy-4-(2-oxo-2-phenylethoxy)phenyl]ethenyl]-7-methyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 169958-81-0 CAPLUS

CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-8-[2-[3-methoxy-4-(1-oxopropoxy)phenyl]ethenyl]-7-methyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 169958-82-1 CAPLUS

CN Propanoic acid, 2,2'-dimethyl-, 4-[2-(1,3-diethyl-2,3,6,7-tetrahydro-7-methyl-2,6-dioxo-1H-purin-8-yl)ethenyl]-2-methoxyphenyl ester, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 169958-83-2 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-[4-(acetyloxy)phenyl]ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 169958-84-3 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-[4-(acetyloxy)-3-methoxyphenyl]ethenyl]-3,7-dihydro-7-methyl-1,3-di-2-propenyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 169958-85-4 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-[3-(acetyloxy)-4-methoxyphenyl]ethenyl]-1,3-diethyl-7-methyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 169958-86-5 CAPLUS

CN 1H-Purine-2,6-dione,
8-[2-[4-(acetyloxy)-3,5-dimethoxyphenyl]ethenyl]-1,3-

diethyl-3,7-dihydro-7-methyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 169958-87-6 CAPLUS

CN 1H-Purine-2,6-dione,

8-[2-[4-(benzoyloxy)-3,5-dimethoxyphenyl]ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 169958-88-7 CAPLUS

CN 1H-Purine-2,6-dione,

8-[2-[4-(acetoxy)-3,5-dimethoxyphenyl]ethenyl]-3,7-dihydro-7-methyl-1,3-di-2-propenyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 169958-89-8 CAPLUS

CN 1H-Purine-2,6-dione,
8-[2-[(E)-3,5-dimethoxyphenyl]ethenyl]-3,7-
dihydro-7-methyl-1,3-di-2-propenyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 169958-90-1 CAPLUS


CN 1H-Purine-2,6-dione, 8-[2-[(E)-3-(acetoxy)phenyl]ethenyl]-1,3-diethyl-3,7-
dihydro-7-methyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 169958-91-2 CAPLUS
CN 1H-Purine-2,6-dione, 8-[2-[3-(benzoyloxy)phenyl]ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 169958-92-3 CAPLUS
CN 1H-Purine-2,6-dione, 8-[2-[2-(acetyloxy)-5-methoxyphenyl]ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 169958-93-4 CAPLUS
CN 1H-Purine-2,6-dione, 8-[2-[2-(benzoyloxy)-5-methoxyphenyl]ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 169958-94-5 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-[(E)-3-methoxyphenyl]ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 169958-95-6 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-[(E)-3-acetoxyphenyl]ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 169958-96-7 CAPLUS

CN 1H-Purine-2,6-dione,
8-[2-[(E)-3-acetoxy-1,3-benzodioxol-5-yl]ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 141807-96-7 155272-00-7, (E)-1,3-Diethyl-8-(3,4-methylenedioxy-5-methoxystyryl)-7-methylxanthine
RL: RCT (Reactant)


(prepn. of xanthine derivs. as adenosine A2 receptor inhibitors)

RN 141807-96-7 CAPLUS

CN 1H-Purine-2,6-dione,

8-[(1E)-2-(3,4-dimethoxyphenyl)ethenyl]-3,7-dihydro-7-methyl-1,3-dipropyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155272-00-7 CAPLUS

CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-8-[(1E)-2-(7-methoxy-1,3-benzodioxol-5-yl)ethenyl]-7-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




IT 151539-46-7P 151539-57-0P 155272-04-1P
 155272-05-2P 160434-48-0P 169958-97-8P
 169958-98-9P 169958-99-0P 169959-00-6P
 169959-01-7P 169959-02-8P 169959-03-9P
 169959-04-0P 169959-05-1P 169959-06-2P
 169959-07-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of xanthine derivs. as adenosine A2 receptor inhibitors)

RN 151539-46-7 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-(3,4-dihydroxyphenyl)ethenyl]-3,7-dihydro-7-methyl-1,3-dipropyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 151539-57-0 CAPLUS

CN 1H-Purine-2,6-dione,
 3,7-dihydro-8-[2-(3-hydroxy-4-methoxyphenyl)ethenyl]-7-methyl-1,3-dipropyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155272-04-1 CAPLUS

CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-8-[2-(3-hydroxy-4-methoxyphenyl)ethenyl]-7-methyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155272-05-2 CAPLUS

CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-8-[2-(4-hydroxyphenyl)ethenyl]-7-methyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 160434-48-0 CAPLUS

CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-8-[2-(4-hydroxy-3-methoxyphenyl)ethenyl]-7-methyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 169958-97-8 CAPLUS

CN 1H-Purine-2,6-dione, 3,7-dihydro-8-[2-[3-methoxy-4-(methoxymethoxy)phenyl]ethenyl]-1,3-dipropyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 169958-98-9 CAPLUS

CN 1H-Purine-2,6-dione, 3,7-dihydro-8-[2-[3-methoxy-4-(methoxymethoxy)phenyl]ethenyl]-7-methyl-1,3-dipropyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 169958-99-0 CAPLUS


CN 1H-Purine-2,6-dione,
3,7-dihydro-8-[2-(4-hydroxy-3-methoxyphenyl)ethenyl]-
7-methyl-1,3-dipropyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 169959-00-6 CAPLUS
CN 1H-Purine-2,6-dione,
3,7-dihydro-8-[2-(4-hydroxy-3-methoxyphenyl)ethenyl]-
7-methyl-1,3-di-2-propenyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 169959-01-7 CAPLUS
CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-8-[2-(4-hydroxy-3,5-dimethoxyphenyl)ethenyl]-7-methyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 169959-02-8 CAPLUS

CN 1H-Purine-2,6-dione, 3,7-dihydro-8-[2-(4-hydroxy-3,5-dimethoxyphenyl)ethenyl]-7-methyl-1,3-di-2-propenyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 169959-03-9 CAPLUS

CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-8-[2-(3-hydroxyphenyl)ethenyl]-7-methyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 169959-04-0 CAPLUS

CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-8-[2-(2-hydroxy-5-methoxyphenyl)ethenyl]-7-methyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 169959-05-1 CAPLUS

CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-8-[2-(2-hydroxy-3-methoxyphenyl)ethenyl]-7-methyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 169959-06-2 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-(2,3-dihydroxyphenyl)ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 169959-07-3 CAPLUS

CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-8-[2-(7-hydroxy-1,3-benzodioxol-5-yl)ethenyl]-7-methyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L22 ANSWER 45 OF 57 CAPLUS COPYRIGHT 2001 ACS

1995:719473 Document No. 123:93344 Bioadhesive pharmaceutical composition used for the controlled release of active ingredient. Rault, Isabelle; Pichon, Gerald; Cuine, Alain (Adir et Cie., Fr.). Can. Pat. Appl. CA 2132512 AA 19950323, 11 pp. (French). CODEN: CPXXEB. APPLICATION: CA 1994-2132512 19940920. PRIORITY: FR 1993-11259 19930922.

AB A bioadhesive pharmaceutical compn. for the controlled release of active ingredient in a buccal cavity or systemically comprises (1) an active principle and (2) a polymer prepnd. by copolymer. of anhydride maleic and methylvinylether or their derivs., (3) and a polymer such as PVP.

Tablets

were prepnd. from granules contg. piribedil 320, maize starch 80, calcium dihydrogen phosphate 278, Gantrez MS955 150, maize starch 160, Mg stearate


10, and colloidal silica 2 g.

IT 138472-18-1

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (controlled-release bioadhesive pharmaceutical compn. contg. polymers)

RN 138472-18-1 CAPLUS

CN 1-Piperazinecarboxamide, N,N-diethyl-4-[3-(2,3,6,7-tetrahydro-1,3,7-trimethyl-2,6-dioxo-1H-purin-8-yl)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L22 ANSWER 46 OF 57 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.

95178812 EMBASE Document No.: 1995178812. Recent progress in modulators of purinergic activity. Bhagwat S.S.; Williams M.. Neuroscience Discovery, Pharmaceutical Products Division, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064-3500, United States. Expert Opinion on Therapeutic Patents 5/6 (547-558) 1995.

ISSN: 1354-3776. CODEN: EOTPEG. Pub. Country: United Kingdom. Language: English. Summary Language: English.

AB As knowledge of the molecular biology of purinergic receptors continues to

evolve, the identification of novel compounds that mimic or block the actions of the purine nucleoside and its nucleotide, ATP, at P1 and P2 receptors subtypes, respectively, has continued to be an area of active interest in the pharmaceutical industry. Adenosine A1 receptor selective agonists with reduced cardiovascular liabilities have been recently described, as have novel A3 receptor selective agonists; both classes of agents showing potential as anti-ischaemic agents in animal models. A number of potent and receptor subtype selective agonists for P2 receptors have also been developed that are being used to characterise the functional role of this receptor class in various mammalian tissues. On the antagonist front, selective A1 receptor antagonists are being targeted

as cognition enhancers while selective A(2a) receptor antagonists have been developed with potential use in **Parkinson's** disease therapy. Despite the clinical failure of Gensia's 'site and event specific' adenosine potentiating agent, Acadesine.RTM., there is continued

interest in compounds that enhance the availability of endogenous adenosine, specifically novel inhibitors of adenosine transport and adenosine kinase.

L22 ANSWER 47 OF 57 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.


95193933 EMBASE Document No.: 1995193933. [Tacrine: First generation of antidementia drugs]. TACRINA: PRIMERA GENERACION DE FARMACOS ANTIDEMENCIA.

Cacabelos R.. Inst. Enf. Sistema Nervioso Central, Centro de Investigacion, Neurociencias Basicas y Clinicas, Apartado de Correos 733, 15080 La Coruna, Spain. Medicina Clinica 105/3 (105-115) 1995.

ISSN: 0025-7753. CODEN: MCLBA2. Pub. Country: Spain. Language: Spanish.

L22 ANSWER 48 OF 57 CAPLUS COPYRIGHT 2001 ACS
1994:400920 Document No. 121:920 Therapeutic agents for **Parkinson**'s disease. Suzuki, Fumio; Shimada, Junichi; Koike, Nobuaki; Nakamura, Joji; Shiozaki, Shizuo; Ichikawa, Shunji; Nonaka, Hiromi (Kyowa Hakko Kogyo Co., Ltd., Japan). Eur. Pat. Appl. EP 590919 A1 19940406, 82 pp.
DESIGNATED STATES: R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE. (English). CODEN: EPXXDW. APPLICATION: EP 1993-307654 19930928. PRIORITY: JP 1992-257834 19920928.

GI



AB Disclosed as therapeutic agents for **Parkinson's** disease are xanthine derivs. of the formula (I): in which: R1 and R2 each represent Me or ethyl; R3 represents hydrogen, C1-C6 straight or branched chain alkyl or C2-C6 straight or branched chain alkenyl or alkynyl; R4 represents C3-C6 cycloalkyl; a -(CH₂)_n-R5 group where n is 0 or an integer of from 1 to 4, and R5 represents Ph, naphthyl or a heterocyclic group or a substituted Ph, naphthyl or heterocyclic group contg. from 1-4 substituents selected from C1-C6 alkyl, C1-C6 alkoxy, hydroxy, halogen, nitro, amino, mono- or di-(C1-C6) alkylamino, trifluoromethyl, benzyloxy, Ph, phenoxy or C1-C6 alkoxy substituted by hydroxy, C1-C6 alkoxy, halogen, amino, azide, carboxy or (C1-C6 alkoxy) carbonyl; or a group were Y1 and Y2 each represent hydrogen, halogen, or C1-C6 straight or branched chain alkyl; and Z represents a group in which R6 represents hydrogen, hydroxy, C1-C6 straight or branched chain alkoxy, halogen, nitro, or amino, and m represents an integer of from 1 to 4, a Ph, naphthyl or heterocyclic group or a substituted Ph, naphthyl or heterocyclic group as defined under R5; and X1 and X2 each represent O or S; or a pharmaceutically acceptable salt thereof.

IT 147700-16-1P 147700-17-2P 147700-32-1P
147700-33-2P 155270-98-7P 155270-99-8P
155271-00-4P 155271-01-5P 155271-02-6P
155271-03-7P 155271-04-8P 155271-05-9P
155271-06-0P 155271-07-1P 155271-08-2P
155271-09-3P 155271-10-6P 155271-11-7P
155271-12-8P 155271-13-9P 155271-14-0P
155271-15-1P 155271-16-2P 155271-17-3P
155271-18-4P 155271-19-5P 155271-20-8P
155271-21-9P 155271-22-0P 155271-23-1P


155271-24-2P 155271-25-3P 155271-26-4P
155271-27-5P 155271-28-6P 155271-29-7P
155271-30-0P 155271-31-1P 155271-32-2P
155271-33-3P 155271-34-4P 155271-35-5P
155271-36-6P 155271-37-7P 155271-38-8P
155271-39-9P 155271-40-2P 155271-41-3P
155271-42-4P 155271-43-5P 155271-44-6P
155271-45-7P 155271-46-8P 155271-47-9P
155271-48-0P 155271-49-1P 155271-50-4P
155271-51-5P 155271-52-6P 155271-53-7P
155271-54-8P 155271-55-9P 155271-56-0P
155271-57-1P 155271-58-2P 155271-59-3P
155271-60-6P 155271-61-7P 155271-62-8P
155271-63-9P 155271-64-0P 155271-65-1P
155271-66-2P 155271-67-3P 155271-68-4P
155271-69-5P 155271-70-8P 155271-71-9P
155271-72-0P 155271-73-1P 155271-74-2P
155271-75-3P 155271-76-4P 155271-77-5P
155271-78-6P 155271-79-7P 155271-80-0P
155271-81-1P 155271-82-2P 155271-83-3P
155271-84-4P 155271-85-5P 155271-86-6P
155271-87-7P 155271-88-8P 155271-89-9P
155271-90-2P 155271-91-3P 155271-92-4P
155271-93-5P 155271-94-6P 155271-95-7P
155271-96-8P 155271-97-9P 155271-98-0P
155271-99-1P 155272-00-7P 155272-01-8P
155272-02-9P 155272-03-0P 155272-04-1P
155272-05-2P 155272-06-3P 155272-07-4P
155272-08-5P 155272-09-6P 155272-10-9P
155272-11-0P 155272-12-1P 155272-13-2P
155272-14-3P 155272-15-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, for treating Parkinson's disease)

RN 147700-16-1 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-(2,3-dimethoxyphenyl)ethenyl]-3,7-dihydro-1,3-dimethyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 147700-17-2 CAPLUS

CN 1H-Purine-2,6-dione,
8-[2-(2,3-dimethoxyphenyl)ethenyl]-3,7-dihydro-1,3,7-trimethyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 147700-32-1 CAPLUS

CN 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl-8-[(2,3,4-trimethoxyphenyl)ethenyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 147700-33-2 CAPLUS

CN 1H-Purine-2,6-dione, 3,7-dihydro-1,3,7-trimethyl-8-[(1E)-2-(2,3,4-trimethoxyphenyl)ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155270-98-7 CAPLUS

CN 1H-Purine-2,6-dione, 8-[(2-(3,4-dimethoxyphenyl)ethenyl)-1,3-diethyl-3,7-dihydro-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155270-99-8 CAPLUS

CN 1H-Purine-2,6-dione, 8-[(1E)-2-(3,4-dimethoxyphenyl)ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-00-4 CAPLUS

CN 1H-Purine-2,6-dione, 8-[(2-(2,3-dimethoxyphenyl)ethenyl]-1,3-diethyl-3,7-dihydro-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-01-5 CAPLUS

CN 1H-Purine-2,6-dione, 8-[(2-(2,3-dimethoxyphenyl)ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-02-6 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-(2,4-dimethoxyphenyl)ethenyl]-1,3-diethyl-3,7-dihydro-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-03-7 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-(2,4-dimethoxyphenyl)ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-04-8 CAPLUS

CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-8-[2-(2,3,4-trimethoxyphenyl)ethenyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-05-9 CAPLUS

CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-7-methyl-8-[2-(2,3,4-trimethoxyphenyl)ethenyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-06-0 CAPLUS

CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-8-[2-(4-methoxy-2,3-dimethylphenyl)ethenyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-07-1 CAPLUS

CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-8-[2-(4-methoxy-2,3-dimethylphenyl)ethenyl]-7-methyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-08-2 CAPLUS

CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-8-[2-(4-methoxy-2,5-dimethylphenyl)ethenyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-09-3 CAPLUS

CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-8-[2-(4-methoxy-2,5-dimethylphenyl)ethenyl]-7-methyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 155271-10-6 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-(2,4-dimethoxy-3-methylphenyl)ethenyl]-1,3-

diethyl-3,7-dihydro-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-11-7 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-(2,4-dimethoxy-3-methylphenyl)ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-12-8 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-(1,3-benzodioxol-5-yl)ethenyl]-1,3-diethyl-3,7-dihydro-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-13-9 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-(1,3-benzodioxol-5-yl)ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-14-0 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-(1,4-dihydro-2,3-benzodioxin-6-yl)ethenyl]-1,3-diethyl-3,7-dihydro-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-15-1 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-(1,4-dihydro-2,3-benzodioxin-6-yl)ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-16-2 CAPLUS

CN 1H-Purine-2,6-dione, 3,7-dihydro-8-[(1E)-2-(4-methoxy-2,3-dimethylphenyl)ethenyl]-1,3-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-17-3 CAPLUS

CN 1H-Purine-2,6-dione, 3,7-dihydro-8-[2-(4-methoxy-2,3-dimethylphenyl)ethenyl]-1,3,7-trimethyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-18-4 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-(1,3-benzodioxol-5-yl)ethenyl]-3,7-dihydro-1,3-dimethyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-19-5 CAPLUS

CN 1H-Purine-2,6-dione,
8-[2-(1,3-benzodioxol-5-yl)ethenyl]-3,7-dihydro-1,3,7-trimethyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-20-8 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-(2,4-dimethoxyphenyl)ethenyl]-3,7-dihydro-1,3-dimethyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-21-9 CAPLUS

CN 1H-Purine-2,6-dione,
8-[2-(2,4-dimethoxyphenyl)ethenyl]-3,7-dihydro-1,3,7-
trimethyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-22-0 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-(2,4-dimethoxy-5-methylphenyl)ethenyl]-3,7-
dihydro-1,3-dimethyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-23-1 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-(2,4-dimethoxy-5-methylphenyl)ethenyl]-3,7-dihydro-1,3,7-trimethyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-24-2 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-(2,4-dimethoxy-3-methylphenyl)ethenyl]-3,7-dihydro-1,3-dimethyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-25-3 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-(2,4-dimethoxy-3-methylphenyl)ethenyl]-3,7-dihydro-1,3,7-trimethyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-26-4 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-(2,5-dimethylphenyl)ethenyl]-1,3-diethyl-3,7-dihydro-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-27-5 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-(2,5-dimethylphenyl)ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-28-6 CAPLUS

CN 1H-Purine-2,6-dione,
8-[2-(4-ethoxyphenyl)ethenyl]-1,3-diethyl-3,7-dihydro-
, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-29-7 CAPLUS

CN 1H-Purine-2,6-dione,
8-[2-(4-ethoxyphenyl)ethenyl]-1,3-diethyl-3,7-dihydro-
7-methyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 155271-30-0 CAPLUS

CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-8-[2-(4-

propoxyphenyl)ethenyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-31-1 CAPLUS

CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-7-methyl-8-[2-(4-propoxyphenyl)ethenyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-32-2 CAPLUS

CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-8-[2-(3-methoxyphenyl)ethenyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-33-3 CAPLUS

CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-8-[2-(3-methoxyphenyl)ethenyl]-7-methyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-34-4 CAPLUS

CN 1H-Purine-2,6-dione,
8-[2-(4-butoxyphenyl)ethenyl]-1,3-diethyl-3,7-dihydro-
, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-35-5 CAPLUS

CN 1H-Purine-2,6-dione,
8-[2-(4-butoxyphenyl)ethenyl]-1,3-diethyl-3,7-dihydro-
7-methyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 155271-36-6 CAPLUS

CN 1H-Purine-2,6-dione,
1,3-diethyl-3,7-dihydro-8-[2-(4-methylphenyl)ethenyl]-

, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-37-7 CAPLUS

CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-7-methyl-8-[2-(4-methylphenyl)ethenyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-38-8 CAPLUS

CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-8-[2-(2-methoxyphenyl)ethenyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-39-9 CAPLUS

CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-8-[2-(2-methoxyphenyl)ethenyl]-7-methyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-40-2 CAPLUS

CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-8-[2-(4-methoxy-3-methylphenyl)ethenyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-41-3 CAPLUS

CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-8-[2-(4-methoxy-3-methylphenyl)ethenyl]-7-methyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-42-4 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-(2-chloro-3,4-dimethoxyphenyl)ethenyl]-1,3-diethyl-3,7-dihydro-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-43-5 CAPLUS

CN 1H-Purine-2,6-dione, 8-[(E)-2-(2-chloro-3,4-dimethoxyphenyl)ethenyl]-1,3-diethyl-, (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-44-6 CAPLUS

CN 1H-Purine-2,6-dione, 8-[(E)-2-(2-chloro-3,4-dimethoxyphenyl)ethenyl]-3,7-dihydro-1,3-dimethyl-, (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-45-7 CAPLUS

CN 1H-Purine-2,6-dione, 8-[(E)-2-(2-chloro-3,4-dimethoxyphenyl)ethenyl]-3,7-dihydro-1,3,7-trimethyl-, (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-46-8 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-(3,4-difluorophenyl)ethenyl]-1,3-diethyl-3,7-dihydro-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-47-9 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-(3,4-difluorophenyl)ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-48-0 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-(3-bromo-4-methoxyphenyl)ethenyl]-1,3-diethyl-3,7-dihydro-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-49-1 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-(3-bromo-4-methoxyphenyl)ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 155271-50-4 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-(3-bromo-4-methoxyphenyl)ethenyl]-3,7-dihydro-1,3-dimethyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155271-51-5 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-(3-bromo-4-methoxyphenyl)ethenyl]-3,7-dihydro-1,3,7-trimethyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.